CD15在初诊急性髓系白血病患者中表达及预后意义OA北大核心CSTPCD

Objective To analyze the expression and prognostic significance of CD 15 in newly diagnosed acute myeloid leukemia(AML)patients,and to investigate the relationship between CD 15 expression and leukemia target gene mutations.Methods The clinical data of 186 newly diagnosed AML patients(except the M3 subtype)who were newly diagnosed at the First People's Hospital of Changzhou from January 1,2018 to April 30,2022 were retrospectively analyzed.Clinical characteristics and prognostic differences were compared between CD15-positive group(CD15+)and CD15-negative group(CD15-)patients.Results Compared with the CD15-group,AML patients in the CD15+group were relatively young(61.0 vs.67.0,P=0.012),had higher white blood cell counts(13.1 × 109/L vs.6.3 × 109/L,P=0.027)and lactate dehydrogenase levels(442.0 U/L vs.287.0 U/L,P=0.023)at initial diagnosis,had a higher proportion of M5 subtype(31.0％vs.12.8％,P=0.003).The ratio of CEBPA mutation(24.0％vs.10.7％,P=0.020)was higher in the CD 15+group than in the CD 15-group,yet the ratio of IDH2 mutation(8.3％vs.28.6％,P＜0.001)was lower.The complete remission(CR)rate induced by 1-2 courses of treatment was 54.0％in the CD 15+group and 34.9％in CD 15-group(P=0.009).The median overall survival(mOS)was 418 days in the CD15+group and 223 days in the CD15-group,and the mOS was significantly longer in the CD 15+group than in the CD 15-group(P=0.027).Conclusion Positive expression of CD 15 indicates a good prognosis.CEBPA and IDH2 mutations differes between CD 15+and CD 15-AMLs.